Flagship Harbor Advisors LLC Has $359,000 Position in GSK plc (NYSE:GSK)

Flagship Harbor Advisors LLC lessened its position in GSK plc (NYSE:GSK) by 2.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,611 shares of the pharmaceutical company’s stock after selling 301 shares during the period. Flagship Harbor Advisors LLC’s holdings in GSK were worth $359,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. FMR LLC raised its stake in GSK by 8.3% during the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after buying an additional 2,224,345 shares during the period. Fisher Asset Management LLC raised its position in shares of GSK by 4.9% during the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after purchasing an additional 870,449 shares during the period. Clifford Capital Partners LLC lifted its holdings in shares of GSK by 14.3% during the 3rd quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock valued at $16,747,000 after purchasing an additional 51,378 shares in the last quarter. Cerity Partners LLC grew its position in shares of GSK by 61.8% in the 3rd quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock valued at $17,728,000 after purchasing an additional 165,556 shares during the period. Finally, Natixis Advisors LLC increased its stake in GSK by 20.0% during the 3rd quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock worth $20,460,000 after purchasing an additional 83,433 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Trading Down 1.1 %

Shares of NYSE:GSK opened at $35.12 on Wednesday. The company’s 50-day moving average price is $33.94 and its two-hundred day moving average price is $37.78. GSK plc has a one year low of $31.72 and a one year high of $45.92. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The stock has a market capitalization of $72.78 billion, a PE ratio of 22.80, a price-to-earnings-growth ratio of 1.31 and a beta of 0.63.

Analyst Ratings Changes

Several research firms have recently weighed in on GSK. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and reduced their price target for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. StockNews.com cut GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 21st. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Six analysts have rated the stock with a hold rating, one has issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.